Travere Therapeutics Soars 10.91% on Analyst Upgrades

On April 18, 2025, Travere Therapeutics saw a significant rise of 10.91% in pre-market trading, indicating strong investor interest and potential market momentum.

Travere Therapeutics has been the subject of several recent research reports. Analysts have given the company a "Moderate Buy" rating with an average target price of $32.08. Evercore ISI upped their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating. Scotiabank restated an “outperform” rating on shares of Travere Therapeutics. Cantor Fitzgerald reiterated an “overweight” rating on shares of Travere Therapeutics. Citigroup upped their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating. JPMorgan Chase & Co. boosted their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating.

Several institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. bought a new position in shares of Travere Therapeutics during the fourth quarter. Geode Capital Management LLC boosted its holdings in Travere Therapeutics by 3.9% in the third quarter. Diversified Trust Co grew its position in shares of Travere Therapeutics by 27.5% during the fourth quarter. R Squared Ltd acquired a new stake in Travere Therapeutics during the fourth quarter. Baader Bank Aktiengesellschaft bought a new position in Travere Therapeutics in the fourth quarter.

Travere Therapeutics, Inc. is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.